Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$36.42 USD
+0.58 (1.62%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $36.45 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COLL 36.42 +0.58(1.62%)
Will COLL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for COLL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COLL
Collegium Pharmaceutical (COLL) Stock Sinks As Market Gains: What You Should Know
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
COLL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Zacks.com featured highlights AppLovin, Kaiser Aluminum, Collegium Pharmaceutical, EMCOR Group and Textron
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Other News for COLL
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
Commit To Purchase Collegium Pharmaceutical At $17.50, Earn 6.7% Annualized Using Options
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
Collegium Pharmaceutical to redeem outstanding 2.625% convertible senior notes due 2026